August 4, 2023
“There is always the risk that interim analyses might occur after the Sufficient Information Threshold has been...
Read article
August 1, 2023
Evaluating the efficacy and safety of novel therapies in rare indications can be challenging due to the difficulty of...
Read article
January 25, 2023
People think in Bayesian terms all the time: we use prior information and the evidence at hand to make decisions in our...
Read article
January 17, 2023
When it comes to rare diseases, a handful of major challenges to drug development arise. Bayesians strategies have...
Read article
January 13, 2023
Bayesian methods, with their ability to facilitate flexibility and learning, are often associated with early-phase...
Read article
January 12, 2023
Statistical methods have long been fundamental to drug development, and advancements in the last few decades in...
Read article
January 4, 2023
Returning to Cytel after the winter holidays, I am excited to begin a year that will likely prove memorable for both my...
Read article
December 27, 2022
Bayesian methods have been playing a key role in transforming clinical research, providing a variety of new...
Read article
December 21, 2022
Perspectives on Enquiry and Evidence features two recurring interview series: Our new Industry Voices series, in which...
Read article
December 16, 2022
Bayesian methods have been playing a key role in transforming clinical research, and Bayesian topics are frequently...
Read article
November 29, 2022
Bayesian methods have continuously played a key role in transforming clinical research in therapeutic areas such as...
Read article
November 18, 2022
In the following interview, Dr. Parvin Fardipour, Quantitative Strategies & Data Science, sits down with Heather...
Read article
October 4, 2022
Integrated Nested Laplacian Approximations (or INLA) are now starting to be used by statisticians as a key tool for...
Read article
October 3, 2022
The wider availability of electronic health data, medical registries, and even larger proprietary datasets means that...
Read article
September 12, 2022
In clinical trials, patient enrollment is often staggered, with data collected sequentially. When designing a clinical...
Read article
September 9, 2022
A new trend has emerged over the last decade that has changed the way many clinical trials are conducted. Unlike...
Read article
August 3, 2022
A number of late-phase clinical trial sponsors remain hesitant to employ Bayesian approaches in confirmatory settings,...
Read article
May 24, 2022
Traditionally, clinical trials are expensive, long in duration, and have low success rate. But with the advent of rich...
Read article
April 21, 2022
Sophisticated Bayesian Methods are gaining a lot of traction as they bring flexibility and speed to clinical trial...
Read article
April 12, 2022
In this edition of the Career Perspectives series, I interview Charles Warne, Associate Director of Biostatistics at...
Read article
April 1, 2022
At the end of every year, scientists from across Cytel’s business units are nominated for Cytel’s Spotlight Awards,...
Read article
March 11, 2022
Every year, sponsors hesitating to use a complex innovative clinical trial design routinely miss opportunities to...
Read article
January 19, 2022
The past two years have been transformative for Cytel. Most notably, the global COVID-19 pandemic unleashed an...
Read article
October 6, 2021
Master Protocols are advanced and innovative clinical trial designs that can evaluate multiple therapies and disease...
Read article
October 1, 2021
The COVID-19 pandemic elevated the challenge of designing and executing clinical trials within a substantially...
Read article
September 24, 2021
We may be familiar with adaptive designs, but their complexity has made them difficult to implement and their benefits...
Read article
September 15, 2021
There is recognized heterogeneity within any given tumor‐type from patient to patient (inter‐patient heterogeneity),...
Read article
July 27, 2021
Program and portfolio optimization creates a framework throughout the course of the clinical development journey, that...
Read article
July 21, 2021
Conducting a transparent, targeted and robust benefit-risk assessment of a new drug or product is one of the most...
Read article
July 2, 2021
Popular statistical designs, such as CRM (O’Quigley et al., 1990), mTPI-2 (Guo et al., 2017), and i3+3 (Liu et al.,...
Read article
June 25, 2021
The main challenge associated with the development of therapies for rare diseases is typically the small study sample...
Read article
June 4, 2021
Bayesian methods have been playing a key role in transforming clinical research in therapeutic areas such as oncology...
Read article
June 3, 2021
Bayesian methods allow for the incorporation of prior knowledge, in terms of either expert opinion from clinicians or...
Read article
May 28, 2021
Advancements in biomarkers and momentum in precision medicine has paved the foundation for complex studies like basket...
Read article
May 12, 2021
Did you know that Bayesian methods can strengthen Frequentist trials through the use of Bayesian decision criteria or...
Read article
April 23, 2021
The urgent need to discover and assess the efficacy and safety of COVID-19 vaccine candidates will affect the future...
Read article
April 14, 2021
In the era of modern clinical development, several companies are turning towards novel and innovative approaches such...
Read article
April 2, 2021
Earlier this month, my colleagues at Cytel Canada published a paper in JCO Clinical Cancer Informatics, offering a...
Read article
March 26, 2021
Former Commissioner of the FDA, Dr. Scott Gottlieb, in several public presentations, would bemoan missed chances to...
Read article
March 5, 2021
Early stage Phase 2 clinical trials are often designed as multi-stage single arm trials, which quickly identify...
Read article
February 26, 2021
In the world of clinical trials, the pace of innovation is accelerating, and approaches such as Bayesian methods are...
Read article
February 18, 2021
In the last few years, there has been a growing interest in historical borrowing or augmented trials. There is an...
Read article
February 12, 2021
In recent times, Single arm trials are being increasingly used to assess new treatment interventions. They establish...
Read article
February 2, 2021
As the use of master protocols becomes more prevalent in drug development, Bayesian methods are extensively used to...
Read article
January 26, 2021
Bayesian models offer a flexible way of incorporating historical controls in the analysis of trial data (whether single...
Read article
December 17, 2020
As Chief Scientific Officer, Dr. Yannis Jemiai plays a pivotal role in maintaining Cytel’s well-established reputation...
Read article
December 16, 2020
As we prepare to close the door on 2020, we asked Pantelis Vlachos, Principal/Strategic Consultant for Cytel, to share...
Read article
November 17, 2020
As a part of Cytel’s "New Horizons Webinar Series", Alind Gupta, Senior Data Scientist, presents case studies from his...
Read article
November 16, 2020
MUCE is a Bayesian solution for cohort expansion trials where multiple dose(s) and multiple indication(s) are tested in...
Read article
October 27, 2020
Cytel recently conducted a webinar on Bayesian Dose-finding Designs for Modern Drug Development, presented by Dr. Yuan...
Read article
October 26, 2020
Pharmaceutical and biotech companies are under pressure to deliver more and deliver faster with fewer resources. The...
Read article
October 22, 2020
In this two-part blog series, we interview Bart Heeg, Vice President HEOR and Founder at Ingress Health (A Cytel...
Read article
October 12, 2020
Cytel and Novartis are together hosting a complimentary Bayesian Virtual Symposium and an Interactive 7-part workshop....
Read article
September 17, 2020
Keeping up with the rapid pace of clinical development means that we need to adopt the innovative or computationally...
Read article
September 4, 2020
On Friday September 11, Cyrus Mehta, co-founder of Cytel, will be delivering a talk to the Heart Failure Collaboratory,...
Read article
August 31, 2020
Pantelis Vlachos, Principal, Strategic Consultant at Cytel, conducted a webinar to introduce the capabilities of East...
Read article
August 26, 2020
As Chief Scientific Officer, Dr. Yannis Jemiai plays a pivotal role in maintaining Cytel’s well-established reputation...
Read article
August 11, 2020
While there is increasing optimism about the discovery of a COVID-19 vaccine, one of the less talked about aspects of...
Read article
July 27, 2020
Cytel is conducting a webinar series on complex innovative trial designs. Dr. Thomas Burnett, Senior Research Associate...
Read article
July 22, 2020
Cytel brings to you a new blog series on technology and Bayesian decision-making by Pantelis Vlachos,...
Read article
June 18, 2020
One of the revelations of the COVID-19 pandemic is that the flexibility and potential of Bayesian designs goes far...
Read article
April 29, 2020
In our previous blog, we spoke with Alind Gupta, who works as a Machine Learning Researcher at Cytel in Canada. The...
Read article
April 20, 2020
Cytel is hosting a webinar on Transparent Machine Learning in Oncology, on April 21, 2020. Our speaker, Alind Gupta,...
Read article
January 30, 2020
The Cytel Trial Design Innovations (CTDI) Webinar Series recently hosted a webinar on designing event-based studies....
Read article
January 16, 2020
January’s Cytel Trial Design Innovations (CTDI) Webinar Series will feature Biostatistician and pioneering Bayesian...
Read article
November 12, 2018
In this blog, we talk with Robert Greene, Founder and President of the HungerNDThirst Foundation, about his upcoming...
Read article
October 5, 2018
We are delighted that Stephen Senn will be joining us at the EUGM on November 14th and 15th in Darmstadt, Germany. In...
Read article
September 27, 2018
In this blog, we talk with Heiko Götte, Senior Expert Biostatistician at Merck about his upcoming presentation at...
Read article
August 15, 2018
Cytel’s 7th East User Group Meeting (EUGM) will take place on November 14 & 15, 2018 at Merck in Darmstadt, Germany,...
Read article
May 30, 2017
A recent paper The case for Bayesian methods in benefit-risk assessment: Overview and future directions (1) co-authored...
Read article
March 24, 2017
Robust go/no-go (GNG) decision-making is essential for effectively managing risk across a clinical portfolio. In early...
Read article
March 2, 2017
We continue our case study series with this example of a Phase 3 design that uses Bayesian decision making combined...
Read article
July 21, 2016
Did you miss our webinar on Single and Dual Agent Dose escalation designs earlier in the year? In this blog we have...
Read article
May 31, 2016
Last week, we were delighted to announce the release of East 6.4 bringing further cutting –edge approaches to the East...
Read article
May 19, 2016
The explosion in healthcare information and “big data “has been one of the most written about topics in the last few...
Read article
March 29, 2016
On March 16th and 17th the 5th East User Group Meeting took place in London. This very successful 2 days saw a variety...
Read article
March 23, 2016
“How many statisticians does it take to ensure at least a 50% chance of a disagreement about p-values?” So questions...
Read article
November 12, 2015
Last week Cytel joined forces with Sanofi/Genzyme to devote a full day of workshops and talks related to modern methods...
Read article
November 10, 2015
Last week Cytel joined forces with Sanofi/Genzyme to devote a full day of workshops and talks related to modern methods...
Read article
October 27, 2015
Here at Cytel we have enjoyed following the debates on the p-value controversy currently taking place on the ASA...
Read article
September 1, 2015
If you’re in the practice of conducting early phase clinical trials, you’ve probably heard that modern trial designs...
Read article
March 20, 2015
Sometimes a new candidate drug for a pediatric study has already been tested on adults for safety and efficacy. We know...
Read article
February 17, 2015
21st Century Cures (also called Cures2015) is a bipartisan initiative undertaken by the Committee on Energy and...
Read article
January 29, 2015
February 2015 marks the five year anniversary of the FDA’s Guidance on Adaptive Design Clinical Trials for Drug and...
Read article
December 9, 2014
When planning a conventional trial, one can anticipate the drug supply necessary for the trial by determining how the...
Read article
November 18, 2014
Statisticians and scientists at Novartis have been at the forefront of developing a new method in early phase oncology...
Read article
October 2, 2014
Sofia S. Villar is a member of the DART (Design and Analysis of Randomised Trials) group at the MRC Biostatistics Unit...
Read article
July 31, 2014
Statisticians at Cytel are staunch advocates of the use of Bayesian methods in clinical trials. This summer's Joint...
Read article
July 15, 2014
Do you design or analyze Phase 1 dose escalation trials? Have you considered methods other than 3+3? This new Cytel...
Read article
May 19, 2014
Pantelis Vlachos, PhD, is a Director at Cytel Consulting. He works with a team of experts who regularly assist clinical...
Read article
May 8, 2014
( Editor's note: This post has been refreshed in December 2016) Model based algorithms for Phase I dose-escalation have...
Read article
